AllAnalyst Report
Morningstar•October 20, 2021
Morningstar•October 20, 2021Abbott Laboratories: Abbott Pushes Forward on Renewed Demand for COVID-19 Tests; Raising Our Fair Value Estimate
Summary
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and immunoas
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Market Digest: FCX, FI, INCY, PG, STX, T, OCApr 25, 2024 •
FI, T, OC, STX, PG, INCY, FCX
- Analyst Report: Boston Scientific CorporationApr 24, 2024 •
BSX
- Analyst Report: Thermo Fisher Scientific Inc.Apr 24, 2024 •
TMO
- EW: Lowering target price to $92.00Apr 24, 2024 •
EW
- A: Raising target price to $146.00Apr 24, 2024 •
A
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.